Sirtuin 1: A target for kidney diseases

Molecular Medicine

Volumn 21, Issue , 2015, Pages 87-97

  Kong, Lili ^a,b   Wu, Hao ^a,b   Zhou, Wenhua ^a   Luo, Manyu ^a,b   Tan, Yi ^b   Miao, Lining ^a   Cai, Lu ^b  

^a THE SECOND HOSPITAL OF JILIN UNIVERSITY   (China)

^b University of Louisville School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN III; ANGIOTENSIN III TYPE 1 RECEPTOR; BECLIN 1; CISPLATIN; CLAUDIN 1; ENDOTHELIAL NITRIC OXIDE SYNTHASE; HIGH MOBILITY GROUP B1 PROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 2ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIVER X RECEPTOR; MICRORNA; NICOTINAMIDE ADENINE DINUCLEOTIDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; PROTEIN BCL 2; PROTEIN P53; REACTIVE OXYGEN METABOLITE; RECEPTOR; RESVERATROL; SIRTUIN 1; SMAD3 PROTEIN; SMAD4 PROTEIN; SMAD7 PROTEIN; STEROL REGULATORY ELEMENT BINDING PROTEIN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR FKHRL1; TRANSCRIPTION FACTOR FOXO; TRANSCRIPTION FACTOR FOXO4; UNCLASSIFIED DRUG; PROTEIN BINDING;

ACETYLATION; ALBUMINURIA; ARTICLE; AUTOPHAGY; BIOGENESIS; BLOOD PRESSURE REGULATION; CELL PROTECTION; CLAUDIN 1 GENE; CPG ISLAND; DEACETYLATION; DIABETIC NEPHROPATHY; DNA METHYLATION; DOWN REGULATION; DRUG ACTIVITY; DRUG CYTOTOXICITY; ENDOTHELIUM CELL; ENZYME REGULATION; EPIGENETICS; EPITHELIAL MESENCHYMAL TRANSITION; FIBROSING ALVEOLITIS; FOXO3 GENE; GENE REPRESSION; GENE TARGETING; GLOMERULONEPHRITIS; GLOMERULUS BASEMENT MEMBRANE; GROWTH INHIBITION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; KIDNEY DISEASE; KIDNEY FIBROSIS; KIDNEY INJURY; LIPID METABOLISM; MITOCHONDRION; NONHUMAN; OBSTRUCTIVE NEPHROPATHY; OXIDATIVE STRESS; PATHOGENESIS; PODOCYTE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN METABOLISM; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; PROTEINURIA; RENAL PROTECTION; SIGNAL TRANSDUCTION; SIRT1 GENE; TUMOR SUPPRESSOR GENE; UBIQUITINATION; ANIMAL; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PATHOLOGY;

ANIMALS; GENE EXPRESSION REGULATION; HUMANS; KIDNEY DISEASES; PROTEIN BINDING; SIGNAL TRANSDUCTION; SIRTUIN 1;

EID: 84930203513     PISSN: 10761551     EISSN: 15283658     Source Type: Journal    
DOI: 10.2119/molmed.2014.00211     Document Type: Article

References (154)

1. Bahari-Javan S, Sananbenesi F, Fischer A. (2014) Histone-acetylation: a link between Alzheimer’s disease and post-traumatic stress disorder? Front. Neurosci. 8:160
2. Bassett SA, Barnett MP. (2014) The role of dietary histone deacetylases (HDACs) inhibitors in health and disease. Nutrients. 6:4273–301
3. Yuan H, et al. (2013) Involvement of p300/CBP and epigenetic histone acetylation in TGF-beta1- mediated gene transcription in mesangial cells. Am. J. Physiol. Renal. Physiol. 304:F601–13
4. Li Y, et al. (2014) Novel role of silent information regulator 1 in acute endothelial cell oxidative stress injury. Biochim. Biophys. Acta. 1842:2246–56
5. Bugyei-Twum A, et al. (2014) High glucose induces Smad activation via the transcriptional coregulator p300 and contributes to cardiac fibrosis and hypertrophy. Cardiovasc. Diabetol. 13:89
6. Hwang YJ, Song J, Kim HR, Hwang KA. (2014) Oleanolic acid regulates NF-κB signaling by suppressing MafK expression in RAW 264.7 cells. BMB Rep. 47:524–9
7. Lee HB, Noh H, Seo JY, Yu MR, Ha H. (2007) Histone deacetylase inhibitors: a novel class of therapeutic agents in diabetic nephropathy. Kidney Int. S61–6
8. Kume S, Thomas MC, Koya D. (2012) Nutrient sensing, autophagy, and diabetic nephropathy. Diabetes. 61:23–9
9. Michishita E, Park JY, Burneskis JM, Barrett JC, Horikawa I. (2005) Evolutionarily conserved and nonconserved cellular localizations and functions of human SIRT proteins. Mol. Biol. Cell. 16:4623–35
10. Xie J, Zhang X, Zhang L. (2013) Negative regulation of inflammation by SIRT1. Pharmacol. Res. 67:60–7
11. Fuks F. (2005) DNA methylation and histone modifications: teaming up to silence genes. Curr. Opin. Genet. Dev. 15:490–5
12. Hasegawa K, et al. (2013) Renal tubular SIRT1 attenuates diabetic albuminuria by epigenetically suppressing Claudin-1 overexpression in podocytes. Nat. Med. 19:1496–504
13. Rea S, et al. (2000) Regulation of chromatin structure by site-specific histone H3 methyltransferases. Nature. 406:593–9
14. Martin C, Zhang Y. (2005) The diverse functions of histone lysine methylation. Nat. Rev. Mol. Cell. Biol. 6:838–49
15. Vaziri H, et al. (2001) hSIR2(SIRT1) functions as an NAD-dependent p53 deacetylase. Cell. 107:149–59
16. Yeung F, et al. (2004) Modulation of NF-kappaBdependent transcription and cell survival by the SIRT1 deacetylase. EMBO J. 23:2369–80
17. Sadoul K, Boyault C, Pabion M, Khochbin S. (2008) Regulation of protein turnover by acetyltransferases and deacetylases. Biochimie. 90:306–12
18. Wang C, Tian L, Popov VM, Pestell RG. (2011) Acetylation and nuclear receptor action. J. Steroid. Biochem. Mol. Biol. 123:91–100
19. Xiong S, Salazar G, Patrushev N, Alexander RW. (2011) FoxO1 mediates an autofeedback loop regulating SIRT1 expression. J. Biol. Chem. 286:5289–99
20. Xu F, et al. (2014) Resveratrol prevention of diabetic nephropathy is associated with the suppression of renal inflammation and mesangial cell proliferation: possible roles of Akt/NF-kappaB pathway. Int. J. Endocrinol. 2014:289327
21. Wen D, et al. (2013) Resveratrol attenuates diabetic nephropathy via modulating angiogenesis. PLoS One.8:e82336
22. Elbe H, et al. (2015) Amelioration of streptozotocininduced diabetic nephropathy by melatonin, quercetin, and resveratrol in rats. Hum. Exp. Toxicol. 34:100–13
23. Huang K, et al. (2013) SIRT1 resists advanced glycation end products-induced expressions of fibronectin and TGF-beta1 by activating the Nrf2/ARE pathway in glomerular mesangial cells. Free Radic. Biol. Med. 65:528–40
24. Gao R, et al. (2014) SIRT1 deletion leads to enhanced inflammation and aggravates endotoxininduced acute kidney injury. PLoS One. 9:e98909
25. Susztak K, Raff AC, Schiffer M, Bottinger EP. (2006) Glucose-induced reactive oxygen species cause apoptosis of podocytes and podocyte depletion at the onset of diabetic nephropathy. Diabetes. 55:225–33
26. Susztak K, Ciccone E, McCue P, Sharma K, Bottinger EP. (2005) Multiple metabolic hits converge on CD36 as novel mediator of tubular epithelial apoptosis in diabetic nephropathy. PLoS Med. 2:e45
27. Bonventre JV. (2012) Can we target tubular damage to prevent renal function decline in diabetes? Semin. Nephrol. 32:452–62
28. Ohse T, et al. (2010) De novo expression of podocyte proteins in parietal epithelial cells during experimental glomerular disease. Am. J. Physiol. Renal Physiol. 298:F702–11
29. Zhang J, et al. (2012) De novo expression of podocyte proteins in parietal epithelial cells in experimental aging nephropathy. Am. J. Physiol. Renal Physiol. 302:F571–80
30. Koda R, et al. (2014) Expression of tight junction protein claudin-1 in human crescentic glomerulonephritis. Int. J. Nephrol. 2014:598670
31. Kim D, et al. (2014) Tamoxifen ameliorates renal tubulointerstitial fibrosis by modulation of estrogen receptor alpha-mediated transforming growth factor-beta1/Smad signaling pathway. Nephrol. Dial. Transplant. 29:2043–53
32. Wei J, et al. (2013) Knockdown of thioredoxininteracting protein ameliorates high glucoseinduced epithelial to mesenchymal transition in renal tubular epithelial cells. Cell Signal. 25:2788–96
33. Das R, et al. (2014) Upregulation of mitochondrial Nox4 mediates TGF-beta-induced apoptosis in cultured mouse podocytes. Am. J. Physiol. Renal Physiol. 306:F155–67
34. Samarakoon R, et al. (2013) Induction of renal fibrotic genes by TGF-beta1 requires EGFR activation, p53 and reactive oxygen species. Cell Signal. 25:2198–209
35. Yao Q, et al. (2008) The role of the TGF/Smad signaling pathway in peritoneal fibrosis induced by peritoneal dialysis solutions. Nephron Exp. Nephrol. 109:e71–8
36. Koutroutsos K, et al. (2014) Effect of Smad pathway activation on podocyte cell cycle regulation: an immunohistochemical evaluation. Ren. Fail. 36:1310–6
37. Liang J, Tian S, Han J, Xiong P. (2014) Resveratrol as a therapeutic agent for renal fibrosis induced by unilateral ureteral obstruction. Ren. Fail. 36:285–91
38. Li J, Qu X, Ricardo SD, Bertram JF, Nikolic-Paterson DJ. (2010) Resveratrol inhibits renal fibrosis in the obstructed kidney: potential role in deacetylation of Smad3. Am. J. Pathol. 177:1065–71
39. Huang XZ, et al. (2014) SIRT1 activation ameliorates renal fibrosis by inhibiting the TGF-beta/Smad3 pathway. J. Cell. Biochem. 115:996–1005
40. Simic P, et al. (2013) SIRT1 suppresses the epithelial- to-mesenchymal transition in cancer metastasis and organ fibrosis. Cell Rep. 3:1175–86
41. Jung DS, et al. (2012) Apoptosis occurs differentially according to glomerular size in diabetic kidney disease. Nephrology Dialysis Transplantation. 27:259–66
42. Chen Y, et al. (2014) Down-regulation of PERKATF4- CHOP pathway by astragaloside IV is associated with the inhibition of endoplasmic reticulum stress-induced podocyte apoptosis in diabetic rats. Cell Physiol. Biochem. 3:1975–87
43. Peng J, et al. (2015) Hyperglycemia, p53, and mitochondrial pathway of apoptosis are involved in the susceptibility of diabetic models to ischemic acute kidney injury. Kidney Int. 87:137–50
44. Wang W, et al. (2015) TRB3 mediates renal tubular cell apoptosis associated with proteinuria. Clin. Exp. Med. 15:167–77
45. Kim D, et al. (2014) Ubiquitination-dependent CARM1 degradation facilitates Notch1-mediated podocyte apoptosis in diabetic nephropathy. Cell Signal. 26:1774–82
46. Meek RL, et al. (2013) Glomerular cell death and inflammation with high-protein diet and diabetes. Nephrol. Dial. Transplant. 28:1711–20
47. Kim DH, et al. (2011) SIRT1 activation by resveratrol ameliorates cisplatin-induced renal injury through deacetylation of p53. Am. J. Physiol. Renal Physiol. 301:F427–35
48. Tikoo K, Singh K, Kabra D, Sharma V, Gaikwad A. (2008) Change in histone H3 phosphorylation, MAP kinase p38, SIR 2 and p53 expression by resveratrol in preventing streptozotocin induced type I diabetic nephropathy. Free Radic. Res. 42:397–404
49. Kume S, et al. (2007) SIRT1 inhibits transforming growth factor beta-induced apoptosis in glomerular mesangial cells via Smad7 deacetylation. J. Biol. Chem. 282:151–8
50. Hasegawa K, et al. (2008) SIRT1 protects against oxidative stress-induced renal tubular cell apoptosis by the bidirectional regulation of catalase expression. Biochem. Biophys. Res. Commun. 372:51–6
51. Chuang PY, et al. 2011 Alteration of forkhead box O (foxo4) acetylation mediates apoptosis of podocytes in diabetes mellitus. PLoS One. 6:e23566
52. Gao F, et al. (2013) Notch pathway is involved in high glucose-induced apoptosis in podocytes via Bcl-2 and p53 pathways. J. Cell. Biochem. 114:1029–38
53. Menini S, et al. (2007) Increased glomerular cell (podocyte) apoptosis in rats with streptozotocininduced diabetes mellitus: role in the development of diabetic glomerular disease. Diabetologia. 50:2591–9
54. Deshpande SD, et al. (2013) Transforming growth factor-beta-induced cross talk between p53 and a microRNA in the pathogenesis of diabetic nephropathy. Diabetes 62:3151–62
55. Han SY, et al. (2006) Apoptosis by cyclosporine in mesangial cells. Transplant. Proc. 38:2244–6
56. Luo J, et al. (2001) Negative control of p53 by Sir2alpha promotes cell survival under stress. Cell. 107:137–48
57. Langley E, et al. (2002) Human SIR2 deacetylates p53 and antagonizes PML/p53-induced cellular senescence. EMBO J. 21:2383–96
58. Brooks CL, Gu W. (2009) How does SIRT1 affect metabolism, senescence and cancer? Nat. Rev. Cancer. 9:123–8
59. Gross DN, van den Heuvel AP, Birnbaum MJ. (2008) The role of FoxO in the regulation of metabolism. Oncogene. 27:2320–36
60. Wang Y, Zhou Y, Graves DT. (2014) FOXO transcription factors: their clinical significance and regulation. Biomed. Res. Int. 2014:925350
61. Brunet A, et al. (2004) Stress-dependent regulation of FOXO transcription factors by the SIRT1 deacetylase. Science. 303:2011–5
62. Nemoto S, Fergusson MM, Finkel T. (2004) Nutrient availability regulates SIRT1 through a forkhead- dependent pathway. Science. 306:2105–8
63. Pedruzzi LM, Stockler-Pinto MB, Leite M Jr, Mafra D. (2012) Nrf2-keap1 system versus NFkappaB: the good and the evil in chronic kidney disease? Biochimie. 94:2461–6
64. Katto J, Engel N, Abbas W, Herbein G, Mahlknecht U. (2013) Transcription factor NFkappaB regulates the expression of the histone deacetylase SIRT1. Clin. Epigenetics. 5:11
65. Hayden MS, Ghosh S. (2008) Shared principles in NF-kappaB signaling. Cell. 132:344–62
66. Lee HJ, et al. (2014) Febuxostat ameliorates diabetic renal injury in a streptozotocin-induced diabetic rat model. Am. J. Nephrol. 40:56–63
67. Roy MS, Janal MN, Crosby J, Donnelly R. (2015) Markers of endothelial dysfunction and inflammation predict progression of diabetic nephropathy in African Americans with type 1 diabetes. Kidney Int. 87:427–33
68. Jialal I, Major AM, Devaraj S. (2014) Global tolllike receptor 4 knockout results in decreased renal inflammation, fibrosis and podocytopathy. J. Diabetes Complications. 28:755–61
69. Wu H, et al. (2014) The role of MicroRNAs in diabetic nephropathy. J. Diabetes Res. 2014:920134
70. Shimo T, et al. (2013) A novel nuclear factor kappaB inhibitor, dehydroxymethylepoxyquinomicin, ameliorates puromycin aminonucleoside-induced nephrosis in mice. Am. J. Nephrol. 37:302–9
71. Xie X, et al. (2012) Polydatin ameliorates experimental diabetes-induced fibronectin through inhibiting the activation of NF-kappaB signaling pathway in rat glomerular mesangial cells. Mol. Cell. Endocrinol. 362:183–93
72. Wu X, et al. (2012) Tanshinone IIA prevents uric acid nephropathy in rats through NF-kappaB inhibition. Planta. Med. 78:866–73
73. Machado RA, et al. (2012) Sodium butyrate decreases the activation of NF-kappaB reducing inflammation inflammation and oxidative damage in the kidney of rats subjected to contrast-induced nephropathy. Nephrol. Dial. Transplant. 27:3136–40
74. Du S, et al. (2009) Suppression of NF-kappaB by cyclosporin a and tacrolimus (FK506) via induction of the C/EBP family: implication for unfolded protein response. J. Immunol. 182:7201–11
75. Salminen A, Kauppinen A, Suuronen T, Kaarniranta K. (2008) SIRT1 longevity factor suppresses NF-kappaB -driven immune responses: regulation of aging via NF-kappaB acetylation? Bioessays. 30:939–42
76. Jung YJ, et al. (2012) SIRT1 overexpression decreases cisplatin-induced acetylation of NF-kappaB p65 subunit and cytotoxicity in renal proximal tubule cells. Biochem. Biophys. Res. Commun. 419:206–10
77. Kitada M, Takeda A, Nagai T, Ito H, Kanasaki K, Koya D. (2011) Dietary restriction ameliorates diabetic nephropathy through anti-inflammatory effects and regulation of the autophagy via restoration of SIRT1 in diabetic Wistar fatty (fa/fa) rats: a model of type 2 diabetes. Exp. Diabetes Res. 2011:908185
78. Dvir-Ginzberg M, et al. (2011) Tumor necrosis factor alpha-mediated cleavage and inactivation of SIRT1 in human osteoarthritic chondrocytes. Arthritis Rheum. 63:2363–73
79. Chalkiadaki A, Guarente L. (2012) High-fat diet triggers inflammation-induced cleavage of SIRT1 in adipose tissue to promote metabolic dysfunction. Cell Metab. 16:180–8
80. Czura CJ, Wang H, Tracey KJ. (2001) Dual roles for HMGB1: DNA binding and cytokine. J. Endotoxin Res. 7:315–21
81. Andersson U, Erlandsson-Harris H, Yang H, Tracey KJ. (2002) HMGB1 as a DNA-binding cytokine. J. Leukoc. Biol. 72:1084–91
82. Scaffidi P, Misteli T, Bianchi ME. (2002) Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature. 418:191–5
83. Karuppagounder V, et al. (2014) Resveratrol attenuates HMGB1 signaling and inflammation in house dust mite-induced atopic dermatitis in mice. Int. Immunopharmacol. 23:617–23
84. Rabadi MM, et al. (2015) High-mobility group box 1 is a novel deacetylation target of Sirtuin1. Kidney Int. 87:95–108
85. Mizushima N, Komatsu M. (2011) Autophagy: renovation of cells and tissues. Cell. 147:728–41
86. Kume S, et al. (2010) Calorie restriction enhances cell adaptation to hypoxia through SIRT1-dependent mitochondrial autophagy in mouse aged kidney. J. Clin. Invest. 120:1043–55
87. Hartleben B, et al. (2010) Autophagy influences glomerular disease susceptibility and maintains podocyte homeostasis in aging mice. J. Clin. Invest. 120:1084–96
88. Jiang M, Liu K, Luo J, Dong Z. (2010) Autophagy is a renoprotective mechanism during in vitro hypoxia and in vivo ischemia-reperfusion injury. Am. J. Pathol. 176:1181–92
89. Kimura T, et al. (2011) Autophagy protects the proximal tubule from degeneration and acute ischemic injury. J. Am. Soc. Nephrol. 22:902–13
90. Periyasamy-Thandavan S, et al. (2008) Autophagy is cytoprotective during cisplatin injury of renal proximal tubular cells. Kidney Int. 74:631–40
91. Inoue K, et al. (2010) Cisplatin-induced macroautophagy occurs prior to apoptosis in proximal tubules in vivo. Clin. Exp. Nephrol. 14:112–22
92. Kaushal GP. (2012) Autophagy protects proximal tubular cells from injury and apoptosis. Kidney Int. 82:1250–3
93. Lee IH, et al. (2008) A role for the NAD-dependent deacetylase SIRT1 in the regulation of autophagy. Proc. Natl. Acad. Sci. U. S. A. 105:3374–9
94. Yamahara K, et al. (2013) The role of autophagy in the pathogenesis of diabetic nephropathy. J. Diabetes Res. 2013:193757
95. Fang L, et al. (2013) Autophagy attenuates diabetic glomerular damage through protection of hyperglycemia-induced podocyte injury. PLoS One. 8:e60546
96. Bellot G, et al. (2009) Hypoxia-induced autophagy is mediated through hypoxia-inducible factor induction of BNIP3 and BNIP3L via their BH3 domains. Mol. Cell. Biol. 29:2570–81
97. Hariharan N, et al. (2010) Deacetylation of FoxO by SIRT1 plays an essential role in mediating starvation-induced autophagy in cardiac myocytes. Circ. Res. 107:1470–82
98. Wu L, Zhang Y, Ma X, Zhang N, Qin G. (2012) The effect of resveratrol on FoxO1 expression in kidneys of diabetic nephropathy rats. Mol. Biol. Rep. 39:9085–93
99. Xia N, et al. (2013) Role of SIRT1 and FOXO factors in eNOS transcriptional activation by resveratrol. Nitric Oxide. 32:29–35
100. Csiszar A, et al. (2009) Resveratrol induces mitochondrial biogenesis in endothelial cells. Am. J. Physiol. Heart Circ. Physiol. 297:H13–20
101. Nisoli E, et al. (2005) Calorie restriction promotes mitochondrial biogenesis by inducing the expression of eNOS. Science. 310:314–7
102. Yu W, Fu YC, Chen CJ, Wang X, Wang W. (2009) SIRT1: a novel target to prevent atherosclerosis. J. Cell. Biochem. 108:10–3
103. Nakagawa T, et al. (2011) Endothelial dysfunction as a potential contributor in diabetic nephropathy. Nat. Rev. Nephrol. 7:36–44
104. Zhao HJ, et al. (2006) Endothelial nitric oxide synthase deficiency produces accelerated nephropathy in diabetic mice. J. Am. Soc. Nephrol. 17:2664–9
105. Nakagawa T, et al. (2007) Diabetic endothelial nitric oxide synthase knockout mice develop advanced diabetic nephropathy. J. Am. Soc. Nephrol. 18:539–50
106. Mattagajasingh I, et al. (2007) SIRT1 promotes endothelium-dependent vascular relaxation by activating endothelial nitric oxide synthase. Proc. Natl. Acad. Sci. U. S. A. 104:14855–60
107. Miyazaki R, et al. (2008) SIRT1, a longevity gene, downregulates angiotensin II type 1 receptor expression in vascular smooth muscle cells. Arterioscler. Thromb. Vasc. Biol. 28:1263–9
108. Wu Z, et al. (1999) Mechanisms controlling mitochondrial biogenesis and respiration through the thermogenic coactivator PGC-1. Cell. 98:115–24
109. Rasbach KA, Schnellmann RG. (2007) Signaling of mitochondrial biogenesis following oxidant injury. J. Biol. Chem. 282:2355–62
110. Lehman JJ, et al. (2000) Peroxisome proliferatoractivated receptor gamma coactivator-1 promotes cardiac mitochondrial biogenesis. J. Clin. Invest. 106:847–56
111. Yuan Y, et al. (2012) Mitochondrial dysfunction accounts for aldosterone-induced epithelial-tomesenchymal transition of renal proximal tubular epithelial cells. Free Radic. Biol. Med. 53:30–43
112. Nemoto S, Fergusson MM, Finkel T. (2005) SIRT1 functionally interacts with the metabolic regulator and transcriptional coactivator PGC- 1α. J. Biol. Chem. 280:16456–60
113. Rodgers JT, et al. (2005) Nutrient control of glucose homeostasis through a complex of PGC- 1alpha and SIRT1. Nature. 434:113–8
114. Yuan Y, et al. (2012) Activation of peroxisome proliferator-activated receptor-gamma coactivator 1alpha ameliorates mitochondrial dysfunction and protects podocytes from aldosteroneinduced injury. Kidney Int. 82:771–89
115. Funk JA, Odejinmi S, Schnellmann RG. (2010) SRT1720 induces mitochondrial biogenesis and rescues mitochondrial function after oxidant injury in renal proximal tubule cells. J. Pharmacol. Exp. Ther. 333:593–601
116. Hu CJ, Wang LY, Chodosh LA, Keith B, Simon MC. (2003) Differential roles of hypoxia-inducible factor 1alpha (HIF-1alpha) and HIF-2alpha in hypoxic gene regulation. Mol. Cell. Biol. 23:9361–74
117. Morita M, et al. (2003) HLF/HIF-2alpha is a key factor in retinopathy of prematurity in association with erythropoietin. EMBO J. 22:1134–46
118. Warnecke C, et al. (2004) Differentiating the functional role of hypoxia-inducible factor (HIF)-1alpha and HIF-2alpha (EPAS-1) by the use of RNA interference: erythropoietin is a HIF-2alpha target gene in Hep3B and Kelly cells. FASEB J. 18:1462–4
119. Haase VH. (2006) Hypoxia-inducible factors in the kidney. Am. J. Physiol. Renal Physiol. 291:F271–81
120. Lim JH, Lee YM, Chun YS, Chen J, Kim JE, Park JW. (2010) Sirtuin 1 modulates cellular responses to hypoxia by deacetylating hypoxiainducible factor 1alpha. Mol. Cell. 38:864–78
121. Dioum EM, et al. (2009) Regulation of hypoxiainducible factor 2alpha signaling by the stressresponsive deacetylase sirtuin 1. Science. 324:1289–93
122. Yoon H, Shin SH, Shin DH, Chun YS, Park JW. (2014) Differential roles of SIRT1 in HIF-1alpha and HIF-2alpha mediated hypoxic responses. Biochem. Biophys. Res. Commun. 444:36–43
123. Walker AK, et al. (2010) Conserved role of SIRT1 orthologs in fasting-dependent inhibition of the lipid/cholesterol regulator SREBP. Genes Dev. 24:1403–17
124. Li X, et al. (2007) SIRT1 deacetylates and positively regulates the nuclear receptor LXR. Mol. Cell. 28:91–106
125. Kemper JK, et al. (2009) FXR acetylation is normally dynamically regulated by p300 and SIRT1 but constitutively elevated in metabolic disease states. Cell Metab. 10:392–404
126. Zhang J. (2007) The direct involvement of SIRT1 in insulin-induced insulin receptor substrate-2 tyrosine phosphorylation. J. Biol. Chem. 282:34356–64
127. Ponnusamy M, et al. (2014) Blocking sirtuin 1 and 2 inhibits renal interstitial fibroblast activation and attenuates renal interstitial fibrosis in obstructive nephropathy. J. Pharmacol. Exp. Ther. 350:243–56
128. Yoshino J, Mills KF, Yoon MJ, Imai S. (2011) Nicotinamide mononucleotide, a key NAD(+) intermediate, treats the pathophysiology of diet- and age-induced diabetes in mice. Cell Metab. 14:528–36
129. Bao L, et al. (2014) Grape seed proanthocyanidin extracts ameliorate podocyte injury by activating peroxisome proliferator-activated receptorgamma coactivator 1alpha in low-dose streptozotocin- and high-carbohydrate/high-fat diet-induced diabetic rats. Food Funct. 5:1872–80
130. Chen D, et al. (2008) Tissue-specific regulation of SIRT1 by calorie restriction. Genes Dev. 22:1753–7
131. Lai CH, et al. (2014) Exercise training enhanced SIRT1 longevity signaling replaces the IGF1 survival pathway to attenuate aging-induced rat heart apoptosis. Age (Dordr). 36:9706
132. Tikoo K, Lodea S, Karpe PA, Kumar S. (2014) Calorie restriction mimicking effects of roflumilast prevents diabetic nephropathy. Biochem. Biophys. Res. Commun. 450:1581–6
133. Hayashida S, et al. (2010) Fasting promotes the expression of SIRT1, an NAD+-dependent protein deacetylase, via activation of PPARalpha in mice. Mol. Cell Biochem. 339:285–92
134. Noriega LG, et al. (2011) CREB and ChREBP oppositely regulate SIRT1 expression in response to energy availability. EMBO Rep. 12:1069–76
135. Motta MC, et al. (2004) Mammalian SIRT1 represses forkhead transcription factors. Cell. 116:551–63
136. Voelter-Mahlknecht S, Mahlknecht U. (2006) Cloning, chromosomal characterization and mapping of the NAD-dependent histone deacetylases gene sirtuin 1. Int. J. Mol. Med. 17:59–67
137. Zhang HN, et al. (2010) Involvement of the p65/RelA subunit of NF-kappaB in TNF-alphainduced SIRT1 expression in vascular smooth muscle cells. Biochem. Biophys. Res. Commun. 397:569–75
138. Zhao Y, et al. (2013) Regulation of TREM2 expression by an NF-small ka, CyrillicB-sensitive miRNA-34a. Neuroreport. 24:318–23
139. Forte E, et al. (2012) The Epstein-Barr virus (EBV)-induced tumor suppressor microRNA MiR-34a is growth promoting in EBV-infected B cells. J. Virol. 86:6889–98
140. Yamakuchi M, Ferlito M, Lowenstein CJ. (2008) miR-34a repression of SIRT1 regulates apoptosis. Proc. Natl. Acad. Sci. U. S. A. 105:13421–6
141. Li J, et al. (2012) Transcriptional activation of microRNA-34a by NF-kappa B in human esophageal cancer cells. BMC Mol. Biol. 13:4
142. Purushotham A, et al. (2009) Hepatocyte-specific deletion of SIRT1 alters fatty acid metabolism and results in hepatic steatosis and inflammation. Cell Metab. 9:327–38
143. Okazaki M, et al. (2010) PPARbeta/delta regulates the human SIRT1 gene transcription via Sp1. Endocr. J. 57:403–13
144. Han L, et al. (2010) SIRT1 is regulated by a PPARγ-SIRT1 negative feedback loop associated with senescence. Nucleic Acids Res. 38:7458–71
145. Canto C, et al. (2009) AMPK regulates energy expenditure by modulating NAD+ metabolism and SIRT1 activity. Nature. 458:1056–60
146. Nin V, et al. (2012) Role of deleted in breast cancer 1 (DBC1) protein in SIRT1 deacetylase activation induced by protein kinase A and AMPactivated protein kinase. J. Biol. Chem. 287:23489–501
147. Hou X, et al. (2008) SIRT1 regulates hepatocyte lipid metabolism through activating AMPactivated protein kinase. J. Biol. Chem. 283:20015–26
148. Lan F, Cacicedo JM, Ruderman N, Ido Y. (2008) SIRT1 modulation of the acetylation status, cytosolic localization, and activity of LKB1: possible role in AMP-activated protein kinase activation. J. Biol. Chem. 283:27628–35
149. Narala SR, et al. (2008) SIRT1 acts as a nutrientsensitive growth suppressor and its loss is associated with increased AMPK and telomerase activity. Mol. Biol. Cell. 19:1210–9
150. Zhu H, et al. (2011) MicroRNA-195 promotes palmitate-induced apoptosis in cardiomyocytes by down-regulating SIRT1. Cardiovasc. Res. 92:75–84
151. Hu Y, Liu J, Wang J, Liu Q. (2011) The controversial links among calorie restriction, SIRT1, and resveratrol. Free Radic. Biol. Med. 51:250–6
152. Grozinger CM, Chao ED, Blackwell HE, Moazed D, Schreiber SL. (2001) Identification of a class of small molecule inhibitors of the sirtuin family of NAD-dependent deacetylases by phenotypic screening. J. Biol. Chem. 276:38837–43
153. Alcain FJ, Villalba JM. (2009) Sirtuin activators. Expert Opin. Ther. Pat. 19:403–14
154. Mai A, et al. (2005) Design, synthesis, and biological evaluation of sirtinol analogues as class III histone/protein deacetylase (Sirtuin) inhibitors. J. Med. Chem. 48:7789–95.